Publicação: Síndrome das pernas inquietas: Diagnóstico e tratamento. Opinião de especialistas Brasileiros
Carregando...
Arquivos
Data
Orientador
Coorientador
Pós-graduação
Curso de graduação
Título da Revista
ISSN da Revista
Título de Volume
Editor
Tipo
Artigo
Direito de acesso
Acesso aberto
Resumo
This article contains the conclusions of the November 17-18, 2006 meeting of the Brazilian Study Group of Restless Legs Syndrome (GBE-SPI) about diagnosis and management of restless legs syndrome (RLS). RLS is characterized by abnormal sensations mostly but not exclusively in the legs which worsen in the evening and are improved by motion of the affected body part. Its diagnosis is solely based on clinical findings. Therapeutic agents with efficacy supported by Class I studies are dopamine agonists, levodopa and gabapentine. Class II studies support the use of slow release valproic acid, clonazepan and oxycodone. The GBE-SPI recommendations for management of SPI are sleep hygiene, withdrawal of medications capable of worsening the condition, treatment of comorbidities and pharmacological agents. The first choice agents are dopaminergic drugs, second choice are gabapentine or oxycodone, and the third choice are clonazepan or slow release valproic acid.
Descrição
Palavras-chave
Clonazepam, Dopamine agonists, Gabapentine, Levodopa, Oxycodone, Periodic leg movements, Pramipexole, Restless legs syndrome, Sleep, Slow release valproic acid, anticonvulsive agent, benzodiazepine derivative, clonazepam, dopamine receptor stimulating agent, gabapentin, levodopa, opiate, oxycodone, valproic acid, abnormal sensation, akathisia, attention deficit disorder, Brazil, clinical practice, controlled study, differential diagnosis, human, peripheral neuropathy, restless legs syndrome, sleep, slow drug release, Anticonvulsants, Diagnosis, Differential, Dopamine Agents, Dopamine Agonists, Humans, Restless Legs Syndrome
Idioma
Português
Como citar
Arquivos de Neuro-Psiquiatria, v. 65, n. 3 A, p. 721-727, 2007.
